Toward the production of bispecific antibody fragments for clinical applications
P CARTER, J RIDGWAY, Z ZHU - Journal of Hematotherapy, 1995 - liebertpub.com
The clinical potential of bispecific antibodies (BsAb) has been hindered by the difficulty of
obtaining clinical grade material, together with the immunogenicity of rodent-derived BsAb in …
obtaining clinical grade material, together with the immunogenicity of rodent-derived BsAb in …
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
K Brischwein, L Parr, S Pflanz, J Volkland… - Journal of …, 2007 - journals.lww.com
Bispecific antibodies have been extensively studied in vitro and in vivo for their use in
redirected tumor cell lysis. A particular challenge of bispecific antibody constructs that …
redirected tumor cell lysis. A particular challenge of bispecific antibody constructs that …
CD8 T cell activation after intravenous administration of CD3× CD19 bispecific antibody in patients with non-Hodgkin lymphoma
GC De Gast, IA Haagen, AA van Houten… - Cancer Immunology …, 1995 - Springer
A bispecific antibody directed to T and B cells (CD3× CD19 bsAb) was daily infused
intravenously in escalating doses from 10 μg up to 5 mg in three patients with chemotherapy …
intravenously in escalating doses from 10 μg up to 5 mg in three patients with chemotherapy …
The evolving role of catumaxomab in gastric cancer
Background: Gastric cancer is a condition with a high medical need. Even after R0 resection
the rate of peritoneal and other distant site recurrences is high. Novel therapeutic …
the rate of peritoneal and other distant site recurrences is high. Novel therapeutic …
Anti‐CD3‐based bispecific antibody designed for therapy of human B‐cell malignancy can induce T‐cell activation by antigen‐dependent and antigen‐independent …
BK Link, SA Kostelny, MS Cole… - … journal of cancer, 1998 - Wiley Online Library
Abstract Anti‐CD3× anti‐B‐cell antigen bispecific monoclonal antibodies (bsAbs) can
redirect T‐cell‐mediated lysis toward malignant B cells. Clinical trials with CD3‐based …
redirect T‐cell‐mediated lysis toward malignant B cells. Clinical trials with CD3‐based …
FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
K Alitalo, O Aprelikova, K Pajusola, E Armstrong… - US Patent …, 2006 - Google Patents
US7034105B2 - FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy -
Google Patents US7034105B2 - FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor …
Google Patents US7034105B2 - FLT4 (VEGFR-3) as a target for tumor imaging and anti-tumor …
Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
K Alitalo, A Kaipainen, R Valtola, L Jussila - US Patent 6,824,777, 2004 - Google Patents
US6824777B1 - Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy - Google
Patents US6824777B1 - Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy …
Patents US6824777B1 - Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy …
The efficacy of CD3 x CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2
IA Haagen, AJ Geerars, WB De Lau, BJ Bast… - 1995 - ashpublications.org
To evaluate the potency by which human T cells are targeted and activated by bispecific
monoclonal antibodies (BsAbs) to lyse tumor cells, a clonogenic assay was developed. The …
monoclonal antibodies (BsAbs) to lyse tumor cells, a clonogenic assay was developed. The …
Chemical production of bispecific antibodies
RF Graziano, P Guptill - Bioconjugation Protocols: Strategies and Methods, 2004 - Springer
This chapter discusses two related methods for creating Fab′× Fab′ chemically linked
BsAb. Both methods require the generation of purified F (ab′) 2 fragments of each antibody …
BsAb. Both methods require the generation of purified F (ab′) 2 fragments of each antibody …
Initiation of humoral and cellular immune responses in patients with refractory Hodgkin's disease by treatment with an anti-CD16/CD30 bispecific antibody
C Renner, F Hartmann, W Jung, C Deisting… - Cancer Immunology …, 2000 - Springer
Fifteen patients with refractory Hodgkin's disease were treated in a dose-escalation trial with
the bispecific monoclonal antibody (bi-mAb) HRS-3/A9, which is directed against the Fcγ …
the bispecific monoclonal antibody (bi-mAb) HRS-3/A9, which is directed against the Fcγ …